一场由减肥“神药”引发的“甜味危机”：糖价腰斩，连梦龙也卖不动了！

Core Insights - The rise of GLP-1 weight loss drugs is shifting consumer preferences from sugary products to protein-rich options, leading to a reevaluation of valuations for commodity and consumer goods companies [1][3] - Sugar demand is being re-priced, with a significant decline in sugar prices and structural pressure on high-sugar categories [1][5] Sugar Market Dynamics - Raw sugar futures have fallen below 14 cents per pound, reaching the lowest level since October 2020, and have halved since the peak at the end of 2023 [1][5] - The USDA has revised its sugar usage forecast down by 23,000 tons to 12.3 million tons for 2026, citing a decline in human consumption [3] - The rapid decline in sugar consumption is attributed to the unexpected speed of demand slowdown in wealthy economies and underwhelming growth in developing markets [6][7] Impact of GLP-1 Drugs - GLP-1 drugs, such as Wegovy and Ozempic, are linked to reduced cravings for sweets, which is affecting sugar consumption patterns [3][6] - Approximately 20% of consumers account for about 65% of sales for sugary products, indicating that changes in behavior among these "super users" could lead to nonlinear declines in sugar demand [6] Stock Market Reactions - The ice cream sector is facing immediate pressure, with the global largest ice cream company, Magnum, reporting a 3% decline in sales, significantly below analyst expectations [8] - Following this, Magnum's stock dropped over 14%, raising concerns about the long-term impact of GLP-1 on high-sugar categories [8] - Unilever, the parent company of Magnum, also experienced a stock decline, with forecasts for sales growth being adjusted downward [9] Protein Market Trends - In contrast to sugar, protein-related raw materials are experiencing price increases, with whey prices nearing record highs due to rising demand for high-protein products [10] - The health trend and the influence of GLP-1 are driving this demand, as healthcare professionals recommend increased protein intake to mitigate muscle loss during weight loss [10] - The approval of the first oral GLP-1 medications is expected to lower usage barriers and expand market penetration [10]